We are live on ! Find out more
KZIA

Kazia Therapeutics

9 hedge funds and large institutions have $400K invested in Kazia Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

29% more funds holding

Funds holding: 79 (+2)

0% more ownership

Funds ownership: 0%0% (+0%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

77% less capital invested

Capital invested by funds: $1.75M → $400K (-$1.35M)

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
2
Closed
2
Calls
Puts
Net Calls
Net Calls Change

KZIA Hedge Fund Activity: Q3 2018 in Review

9 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2018, worth a combined $400K — down 77% from $1.75M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new KZIA positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Transform Wealth, opening a new position worth an estimated $361K. The largest seller was Cornerstone Wealth Management, exiting entirely with an estimated $1.43M sold.

  • 9 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2018, up from 7 in Q2 2018.
  • Funds reported $400K of Kazia Therapeutics stock for Q3 2018, down 77% quarter-over-quarter.
  • 4 funds opened new Kazia Therapeutics positions in Q3 2018 and 2 closed out, a net change of +2 holders.
  • The largest Kazia Therapeutics buyer in Q3 2018 was Transform Wealth, an estimated $361K added.
  • The largest Kazia Therapeutics seller in Q3 2018 was Cornerstone Wealth Management, an estimated $1.43M sold.

Based on aggregated 13F filings for Q3 2018.